T1	Participants 57 86	myometrium and uterine myomas
T2	Participants 90 117	gnRH analogue-treated women
T3	Participants 494 561	women with uterine myomas, untreated or treated with GnRH analogue.
T4	Participants 1212 1231	females with myomas